Ministers are weighing in on the future of Palantir UK government contracts, yet two of Britain’s best-known decision intelligence companies have already changed hands, and the third is weighing a listing. What happens next may say as much about who can build for the state as about who can sell to it.
In March, Marc Warner, who co-founded Faculty in 2014, became chief technology officer of Accenture.
Faculty, whose work includes the NHS Covid-19 early warning system, had just been sold to the consultancy in a deal reported at more than $1bn, and its decision intelligence product, Frontier, moved into Accenture’s portfolio with it.
Months later, Andy Burnham’s government is searching for a British alternative to the company Faculty, which has been described as competing for public sector work.
Palantir UK government spending and commitments have reached almost £1bn since 2014 on one contract, and Faculty is no longer independent at the moment the state starts shopping for homegrown options.
Palantir UK government contracts reach well beyond the NHS
The review reported so far centres on the NHS platform, with the Ministry of Defence relationship also being examined; there is no reported review of most of the other contracts below.
The NHS draws the headlines, but the work spans defence, energy and policing. The Ministry of Defence gave Palantir a three-year, £240.6m agreement in December 2025 without a competitive tender, a direct award the government has said followed the Procurement Act 2023.
The National Energy System Operator made its own £21.2m direct award on technical grounds, with a competitive process promised for the longer term. Five East Midlands police forces are reported to be ending a trial of its Nectar tool, and London’s mayor blocked a £50m Metropolitan Police deal over procurement failings, a decision Palantir is contesting.
Palantir says more than a sixth of its global workforce is based in the UK and that all UK government data is stored here. Its critics say the sheer scale of the Palantir UK government footprint is the problem.
“the British state is in the early stages of addiction to Palantir”—Clive Lewis, Labour MP
The NHS federated data platform is the test
The most contested piece is the £330m Palantir NHS contract to run the NHS federated data platform, awarded in November 2023 and now approaching a break clause in February 2027.
Two Commons committees have urged the government to find an alternative. Ministers are reportedly weighing a roughly one-year extension of the Palantir NHS contract while a British replacement is developed or splitting the platform between several suppliers.
Three or four British companies are reportedly under consideration, including Quantexa, which also bid for the platform in 2023.
“There is serious mistrust of the Palantir-created Federated Data Platform…”— Health and Social Care Committee letter
Not everyone who worked on the platform thinks replacement is realistic.
“There is no platform that can replace the functionality Palantir provides”— Tom Bartlett, former deputy director, NHS England
A definitional problem sits underneath all of this.
Burnham’s push is aimed at British companies, yet officials reportedly say the procurement criteria are not legally tied to country of origin, and some in Labour point out that Palantir’s UK subsidiary could meet the test.
Three decision intelligence companies, three routes
Gartner published its first Magic Quadrant for decision intelligence platforms in January, evaluating 17 vendors. The Gartner Magic Quadrant companies named Leaders included IBM, FICO, SAS and ACTICO, alongside Quantexa.
Peak, from Manchester, joined UiPath in March 2025, and its decision intelligence was built around pricing, inventory and supply chains for retailers and manufacturers, not banks or governments.
Faculty went to Accenture, which is headquartered in Dublin.
Quantexa remains independent, valued at $2.6bn after a $175m Series F in 2025. Whether the Gartner Magic Quadrant companies selling “decision intelligence” to buyers as different as a retailer and a tax authority amount to a single sector is a fair question.
Read next: How Vishal Marria Built Quantexa Into a $2.6bn Company
What trust looks like when customers are also shareholders
Quantexa’s customers include HSBC, Standard Chartered and Danske Bank, along with the Public Sector Fraud Authority at the Cabinet Office.
Its platform is built around entity resolution and graph analytics, tools for linking scattered records to surface hidden connections, and Standard Chartered uses it for anti-money laundering and wider financial crime work.
The Public Sector Fraud Authority holds a £4m contract with Quantexa that builds on earlier Cabinet Office work using it to flag potential fraud in the Bounce Back Loan Scheme, and HMRC announced a 10-year, £175m deal in May to combine its own data with external sources to spot fraud and error. Quantexa says automated decisions about taxpayers will still need human verification. HSBC, BNY and ABN AMRO have also taken part in Quantexa’s funding rounds, so some of the banks that use the product own part of it. We think that overlap is worth keeping in view when reading the customer list.
Ownership is shifting as well. Warburg Pincus, which first invested in 2021, is reportedly exploring a sale of its 9–10% stake, and chief executive Vishal Marria says the company has been IPO-ready since January.
“We can list in the UK or the U.S., or both”— Vishal Marria, CEO, Quantexa
Marria also argues that data sovereignty depends on whether customers keep ownership of their data and can move it elsewhere when a contract ends, rather than on where a supplier is headquartered, and he says Quantexa’s software works with existing systems and reduces the risk of vendor lock-in. That position supports Quantexa’s pitch to the NHS, and it would serve Palantir’s case equally well.
The Sovereign AI Unit offers first contracts, with IP kept
The £500m Sovereign AI Unit launched in April, and its £100m R&D procurement scheme opened the first competitions at the end of August, in the middle of the argument over Palantir UK government work. Contracts run from £250,000 to £10m, and companies keep their intellectual property. The government describes the unit as acting like “a venture capital fund with the muscle of the state behind it.” The gap between a demonstrator contract of up to £10m and a £330m national platform is the distance any British challenger has to cross.
What we’d still like to know
Whatever happens to Palantir UK government contracts in 2027, the break clause arrives with few answers attached. We don’t yet know who is on the shortlist beyond the names reported, whether ministers will extend the Palantir NHS contract while a replacement is built, or what “British” will mean in practice for a company’s headquarters, ownership, or payroll.
If Quantexa lists abroad or passes into new hands, would a deal to run the NHS federated data platform still count as sovereign?
Could Faculty, now part of Accenture, still compete for public sector work like this?
And finally, will the Sovereign AI money keep companies in the UK as they grow, or send the next Faculty and Peak abroad?
This piece is based on secondary research drawn from public reporting, company announcements, and government publications. If you are building in this space and would like to talk, we would welcome the conversation.
Sources: Accenture newsroom and Business Wire (Faculty acquisition, January and March 2026); BusinessCloud (March 2026); UiPath/Business Wire and TechCrunch (Peak, March 2025); Gartner Magic Quadrant for Decision Intelligence Platforms (January 2026), with vendor announcements from Quantexa, ACTICO and SAS; Reuters (19 August 2026); BBC News reporting on the HMRC–Quantexa deal (May 2026), as relayed by Engadget and trade press; GOV.UK (Cabinet Office/Public Sector Fraud Authority release; Sovereign AI R&D Procurement Scheme, 31 August 2026); sovereignai.gov.uk; UK Parliament, Health and Social Care Committee (letter to the Health Innovation Minister) and Science, Innovation and Technology Committee (June 2026); Computer Weekly; The Register; Hansard (10 February 2026); The Nerve (2 October 2026); Financial Times reporting of 1 October 2026 as relayed by SFG Media and Nelson Advisors; Boardwave (April 2026); TechCrunch, Finextra and Retail Banker International (Quantexa customers and funding).
